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Hereditary leiomyomatosis and renal cell cancer is a recently described hereditary cancer syndrome in which affected individuals are
predisposed to the development of leiomyomas of the skin and uterus. In addition, this clinical entity also can result in the
development of biologically aggressive kidney cancer. Affected individuals harbour a germline mutation of the fumarate hydratase (FH)
gene, which encodes an enzyme that catalyses conversion of fumarate to malate in the Kreb’s cycle. Thus far, proposed mechanisms
for carcinogeneis associated with this syndrome include aberrant apoptosis, oxidative stress, and pseudohypoxic drive. At this time,
the majority of accumulating data support a role for pseudohypoxic drive in tumour development. The link between FH mutation and
pseudohypoxic drive may reside in the biochemical alterations resulting from diminished/absent FH activity. These biochemical
derangements may interfere with oxygen homeostasis and result in a cellular environment conducive to tumour formation.
British Journal of Cancer (2007) 96, 403–407. doi:10.1038/sj.bjc.6603547 www.bjcancer.com
Published online 9 January 2007
& 2007 Cancer Research UK
Keywords: hereditary leiomyomatosis and renal cell cancer; kidney cancer; fumarate hydratase; hypoxia inducible factor
                                       
Kidney cancers represent a heterogeneous group of malignancies
linked by the primary site of pathology. Despite originating in the
kidney, renal cell carcinoma (RCC) is a disease with varying genetic
basis. Biologic characterisation of this disease has been greatly aided
by the investigation of families with multiple members affected by
RCC. Probably the earliest and best-characterised familial form of
kidney cancer is von-Hippel Lindau (VHL). von-Hippel Lindau
families are susceptible to the development of clear cell histology
RCC owing to inherited alterations of the VHL gene (Latif et al,
1993). Moreover, the VHL gene has also been implicated in the
development of a significant proportion of sporadic clear cell kidney
cancers (Gnarra et al, 1994). In addition to VHL, other genes have
been identified to be involved with inherited kidney cancer, for
example, c-met in hereditary papillary renal carcinoma (Schmidt
et al,1 9 9 7 ) .
More recently, an inherited neoplastic syndrome has been
identified and referred to as hereditary leiomyomatosis and renal
cell cancer (HLRCC) (Launonen et al, 2001). Families affected by
HLRCC possess a germline-inactivating mutation in the gene
encoding the Kreb’s cycle enzyme, fumarate hydratase (FH)
(Tomlinson et al, 2002). These individuals are predisposed to
development of benign leiomyomas of the skin and uterus as
well as highly aggressive kidney cancers (Launonen et al, 2001;
Tomlinson et al, 2002; Wei et al, 2006). Somatic genetic events
inactivating the second FH allele in leiomyomas and kidney
tumours have been identified (Tomlinson et al, 2002). Kidney
cancers are less penetrant than leiomyomatous manifestations in
HLRCC-affected families (Wei et al, 2006). Renal tumours have
been identified in approximately one-third of HLRCC families
evaluated at the National Cancer Institute; however, family
recruitment criteria may have favoured selection for families
affected by kidney cancer (Wei et al, 2006). Kidney tumours that
develop in patients with HLRCC are biologically very aggressive.
Of 13 individuals identified with kidney cancer in the first reported
cohort of North American families, nine patients succumbed to
metastatic disease within 5 years from initial diagnosis (Toro et al,
2003). As a result, regular screening of affected HLRCC individuals
is advocated. Although FH mutation has been linked to the
development of RCC in the context of HLRCC, its role in sporadic
kidney cancers appears to be limited (Kiuru et al, 2002). Morris
et al (2004) examined DNA from RCC samples. They were unable
to detect FH mutations in all nine cell lines tested. Of the 46
tumour samples examined, no mutations could be identified in 42.
In the remaining four tumour samples, the alteration identified
was a silent single-nucleotide polymorphism (Morris et al, 2004).
In addition, Kiuru et al (2002) were unable to identify FH
mutations in 52 sporadic RCCs. These data suggest that biallelic
loss of FH is necessary to promote HLRCC-associated renal
tumorigenesis. As complete loss of FH activity is developmentally
disfavoured owing to the severe energy deprivation imposed on the
developing brain by such a genetic defect, appearance of HLRCC
appears to be restricted to those otherwise healthy individuals
hemizygous for FH in whom a somatic mutation has inactivated
the second allele. Despite a potentially limited role for FH in
sporadic RCC, investigation of the molecular basis of HLRCC
provides a unique opportunity to identify signalling pathways that
may be important for kidney cancer aetiology.
ROLE OF FH IN KIDNEY CANCER
The role of FH alterations in the development of HLRCC is under
intense investigation. As mentioned, FH is an enzyme of the Kreb’s
cycle that catalyses the conversion of fumarate to malate. It
Received 4 September 2006; revised 17 November 2006; accepted 23
November 2006; published online 9 January 2007
*Correspondence: Dr L Neckers, Urologic Oncology Branch, Center for
Cancer Research, National Cancer Institute, 10 Center Drive, Bldg 10
CRC Room 1-5940, Bethesda, MD 20892-1107, USA;
E-mail: len@helix.nih.gov
British Journal of Cancer (2007) 96, 403–407
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.comappears that FH acts as a tumour suppressor gene and fits
Knudson’s two-hit model (Tomlinson et al, 2002). Patients with
HLRCC inherit a mutant copy of the FH gene as well as a wild-type
copy. Tumour formation appears to occur when there is somatic
alteration of the wild-type copy (Tomlinson et al, 2002). Although
allelic loss appears to be the most common alteration, insertion
and missense mutations have also been described in kidney
tumours from patients with germline mutations of FH (Tomlinson
et al, 2002).
Given the reliance of cells on the mitochondrion to generate
adenosine triphosphate by oxidative phosphorylation, it seems
that a cell with a defective tricarboxylic (TCA) cycle would be at a
disadvantage. However, FH is not the only TCA enzyme whose
inactivation is linked to neoplasia. Mutations of succinate
dehydrogenase (SDH) have been implicated in the development
of a cancer syndrome referred to as hereditary paraganglioma and
pheochromocytoma (HPGL). Succinate dehydrogenase catalyses
the conversion of succinate to fumarate. In contrast to FH, which
functions as a homotetramer (Wei et al, 2006), SDH consists of
four different subunits, named A, B, C, and D (Gottlieb and
Tomlinson, 2005). Mutations of SDH-B, SDH-C, and SDH-D have
all been identified with HPGL (Baysal et al, 2000; Niemann and
Muller, 2000; Astuti et al, 2001).
Postulated mechanisms for these inherited cancer syndromes
include aberrant apoptosis, oxidative stress, and pseudohypoxic
drive (Gottlieb and Tomlinson, 2005). Of these, pseudohypoxic
drive has the most supportive evidence based on both clinical and
basic investigations. Pseudohypoxic drive refers to the activation
of hypoxia response signalling pathways under normal oxygen
conditions. The concept of pseudohypoxia is best understood in
the context of the VHL pathway.
THE VHL PATHWAY AND HIF DYSREGULATION
VHL is a tumour suppressor gene involved in the development of
clear cell RCC. The VHL protein product, hereafter referred to as
pVHL, is part of a complex signalling cascade that modulates a
cell’s oxygen-dependent gene expression. In normoxic conditions,
pVHL is known to associate with several proteins including
Cul-2, Elongin B, and Elongin C to form the VHL complex
(Figure 1) (Kibel et al, 1995; Linehan et al, 2003). Intact VHL
complex possesses ubiquitin ligase activity that targets proteins for
degradation (Pause et al, 1997). Hypoxia inducible factor 1a (HIF-
1a) and HIF-2a are two of the proteins targeted for degradation by
the VHL complex under normoxic conditions (Ivan et al, 2001;
Kaelin Jr, 2005). These two proteins are key regulators of oxygen
homeostasis (Kaelin Jr, 2005). They are transcription factors
involved in the expression of genes involved in nutrient
catabolism, angiogenesis, as well as cell growth and differentiation
(Semenza, 1999). Target genes of the HIF transcription factors
include vascular endothelial growth factor (VEGF), glucose
transporter 1 (GLUT1), platelet-derived growth factor (PDGF),
transforming growth factor-a (TGF-a), and erythropoietin (EPO).
VHL complex recognition of HIF requires the hydroxylation of
conserved proline residues of the HIF protein (Ivan et al, 2001).
Hydroxylation of HIF is carried out by a family of enzymes
referred to as HIF prolyl hydroxylases (HPHs), also referred to as
prolyl hydroxylases (Kaelin, 2005). The enzymatic hydroxylation
of HIF requires molecular oxygen and 2-oxoglutarate (2-OG) as
cosubstrates (Kaelin Jr, 2005). In addition, ascorbate and iron are
required cofactors for HPH catalytic activity (Kaelin Jr, 2005).
Under hypoxic conditions, molecular oxygen is limited. As a
result, HIF remains unhydroxylated. In the unhydroxylated state,
HIF avoids ubiquitination by the VHL complex, and is therefore
available to activate the transcription of the aforementioned genes.
In instances where VHL mutations are present, HIF is able to avoid
degradation, thus creating a pseudohypoxic state. Indeed, upre-
gulation of both HIF-1a and HIF-2a has been identified in clear cell
RCCs along with concomitant expression of HIF downstream
target genes (Wiesener et al, 2001; Zhang et al, 2006). Yet there
may be differential contribution of the HIF proteins to tumor-
igensis. This is in part supported by the contrasting findings in the
RCC cell line 786-O, which lacks pVHL that are tumorigenic in
mouse xenograft models. Reintroduction of pVHL diminishes
tumour formation in xenograft models consistent with the tumour
suppressor function of pVHL (Iliopoulos et al, 1995). However, the
tumour supressor function of pVHL is mitigate in xenograft
models with introduction of an HIF-2a mutant that avoids
ubiquitin-mediated degradation (Kondo et al, 2002). On the other
hand, the tumour-suppressor function of pVHL remains intact
despite the presence of the corresponding HIF-1a mutant
(Maranchie et al, 2002). These and other studies have contributed
to the current belief that HIF-2a may be more important to the
formation of clear cell RCC.
HLRCC AND PSEUDOHYPOXIC DRIVE
Several reports provide evidence of HIF accumulation in both
leiomyomas and renal tumours from HLRCC individuals. Con-
current studies in HPGL have also implicated pseudohypoxic drive
and by analogy support involvement of pseudohypoxia in the
aetiology of HLRCC kidney tumours. Given that both FH and SDH
represent TCA cycle enzymes, it seems reasonable to consider the
possibility that their inactivation may uncover a similar mechan-
ism linking mitochondrial dysfunction with oncogenesis.
The notion of TCA cycle dysregulation and pseudohypoxic drive
was initially derived from studies in paraganglioma. The increased
frequency of carotid body paragangliomas in individuals who
resided in higher altitudes (Pacheco-Ojeda et al, 1988) suggested
a role for chronic hypoxia (Gimenez-Roqueplo et al, 2001). The
similarity between HPGL tumours from patients with germline
SDHD mutations and normal carotid body tissue exposed to
chronic hypoxia led Baysal et al (2000) to suggest that SDHD was a
critical gene involved in oxygen sensing. Furthermore, they
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Figure 1 HIF and the VHL complex. Under normoxic conditions, HIF is
hydroxylated by HPH. Hypoxia inducible factor 1a prolyl hydroxylases
activity requires molecular oxygen, 2-OG, ascorbate (Asc), and iron (Fe).
Following hydroxylation (represented by the OH group), HIF is recognised
by the VHL complex and targeted for degradation. Pseudohypoxia results
from VHL alterations that result in HIF accumulation with upregulation of
potentially tumorigenic genes.
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‘hypoxic stimulation’ and cellular proliferation. Tumours from
HPGL patients with SDHD mutations revealed enhanced expres-
sion of HIF as well as VEGF (Gimenez-Roqueplo et al, 2001). These
and other studies helped formulate the rationale for evaluating the
role of pseudohypoxic drive in HLRCC.
Pollard et al (2005b) examined HIF-1a expression in kidney
tumours (both papillary and collecting duct histologies) in patients
with HLRCC. Their findings in kidney tumours were compelling
for activation of hypoxic pathways. In all renal tumours examined,
they noted strong HIF-1a staining in the nuclei of tumour cells.
This finding was also confirmed by immunoblotting, as HIF-1a
was easily detected in tumour cell lysate with no detectable HIF-1a
in normal kidney lysate (Pollard et al, 2005b). Isaacs et al (2005)
also examined HIF-1a expression in kidney tumours from patients
with HLRCC. Interestingly, six of the seven tumours were from
patients less than 40 years of age. HIF expression, evaluated by
immunohistochemisty, was determined in cancerous tissues in
relation to normal, matched renal parenchyma from the same
patient. Both HIF-1a and HIF-2a were found to be significantly
overexpressed in HLRCC renal tumours, but HIF-1a expression
seemed to be preferentially increased compared to HIF-2a.
Further supportive evidence comes from observation of the
upregulated downstream HIF targets in tumour tissues isolated
from patients with HLRCC. Pollard et al (2005a) examined
microvessel density in HLRCC uterine leiomyomas. Vascular
density, determined by immunohistochemical detection of the
vascular endothelial markers, was significantly higher in HLRCC
uterine leiomyomas as compared to non-leiomyomatous myo-
metrium from HLRCC women. Furthermore, there was a
statistically significant higher vascular density in HLRCC leiomyo-
mas compared to sporadic leiomyomas or normal myometrium
procured from women without HLRCC (Pollard et al, 2005a).
Interestingly, sporadic uterine leiomyomas actually had dimin-
ished vascular density as compared to normal myometrium
controls from matched patients. In concordance with this finding,
in situ hybridisation studies revealed upregulation of VEGF
transcripts in HLRCC uterine leiomyomas in comparison to
normal myometrium (from HLRCC and non-HLRCC women) as
well as sporadic uterine leiomyomas (Pollard et al, 2005a). These
findings were confirmed by quantitative real-time PCR data that
revealed enhanced expression of VEGF (1.4–3.5-fold) as compared
to patient-matched normal myometrium. In addition, other
hypoxia-responsive gene changes were also found in HLRCC
leiomyomas including downregulation of TSP1, a known anti-
angiogenesis factor (Pollard et al, 2005a). This investigation
suggests significant differences between sporadic leiomyomas
and HLRCC leiomyomas with regard to mechanism of tumorigen-
esis. Indeed, complementary evidence for different mechanisms is
indicated by the finding that biallelic FH alterations are found in
an extremely small subset of sporadic uterine leiomyomas
(Lehtonen et al, 2004). Further investigation subsequently revealed
moderate HIF-1a expression in HLRCC fibroids with weak/
moderate staining of surrounding myometrium (Pollard et al,
2005b). Although overexpression of HIF-1a in HLRCC fibroids is
less than VEGF, the concomitant upregulation of these proteins
suggests that pseudohypoxic activation contributes to the genesis
of uterine leiomyomas in HLRCC patients. There is also supportive
evidence for activation of hypoxic pathways in kidney tumours
from HLRCC patients. Isaacs et al (2005) identified enhanced
GLUT1 expression by immunohistochemisty in multiple HLRCC
kidney tumours as compared to normal renal tissue.
Although there is clear evidence of activation of pseudohypoxic
pathways in HLRCC tumours, the molecular mechanism under-
lying this phenomenon remains obscure. Unlike the involvement
of pVHL in HIF degradation, there is no direct link between the FH
and HIF proteins. The answer may lie in the biochemical
alterations that result from the absence of an intact FH enzyme.
As noted earlier, FH catalyses the hydration of fumarate to form
malate. The absence of FH could presumably result in chronically
elevated levels of fumarate and altered levels of other TCA
intermediates and molecules indirectly linked to the TCA cycle.
There is direct evidence to support elevation of intracellular
fumarate secondary to reduced FH activity as a proximal cause of
pseudohypoxia. Isaacs et al (2005) transfected the FH wild-type
lung carcinoma cell line A549 with small interfering RNA (siRNA)
targeting FH. The intracellular fumarate level rapidly doubled in
treated A549 cells. Although these data support the possibility that
reduced FH expression may acutely result in elevated intracellular
fumarate, they may not be representative of cellular changes
associated with long-term absence of FH expression. However,
Pollard et al (2005b) addressed this issue by examining levels of
various Kreb’s cycle intermediates in uterine leiomyomas from
HLRCC patients. Fumarate levels in these HLRCC fibroids were
markedly elevated (over 200-fold) as compared to levels in normal
myometrium from both non-HLRCC and HLRCC patients.
Interestingly, succinate levels were also found to be elevated in
HLRCC fibroids, but to a lesser degree than fumarate. Although
similar analysis of HLRCC kidney tumours does not yet exist, these
findings certainly support the possibility that elevated fumarate
levels may represent a chronic cellular response to impaired/
absent FH activity.
Given the likelihood that cells with impaired/absent FH activity
have elevated levels of fumarate, the question remains as to why
this results in a cellular milieu prone to tumorigenesis. Isaacs et al
(2005) examined the potential link between fumarate and HIF
stability utilising a known inhibitor of both FH and SDH, 3-
nitropropionic acid (Coles et al, 1979; Porter and Bright, 1980). In
A549 lung carcinoma cells, inhibition of FH activity in addition
to exogenous administration of fumarate resulted in elevated
HIF levels in nuclear protein extracts. Furthermore, similar
experiments performed in the presence of cycloheximide, a
protein synthesis inhibitor, revealed that the increased level of
HIF was due to increased HIF protein half-life (approximately five-
fold longer than control treatment). Combination treatment of FH
inhibitor and fumarate resulted in a diminished level of hydro-
xylated HIF. As noted earlier, hydroxylated HIF is the form of HIF
that is recognisable by the VHL complex for degradation. Given
these data, Isaacs et al (2005) further examined the effect of
fumarate on HPH-dependent HIF hydroxylation, and they found
that the ratio of hydroxylated HIF to total HIF protein was
dramatically reduced by pharmacologic elevation of intracellular
fumarate level. As noted earlier, HIF degradation relies on the
hydroxylation of proline residues by the HPH enzymes, requiring
molecular oxygen and 2-OG as cosubstrates. In cell-free systems,
Isaacs et al (2005) found fumarate to be a potent competitive
inhibitor of the HPH cosubstrate 2-OG (Figure 2). Given evidence
of fumarate elevation in FH null tumours, these findings provide
a clear rationale for pseudohypoxic drive in HLRCC being
HIF-dependent.
Further supporting the link between Kreb’s cycle dysfunction
and pseudohypoxic drive are previous studies investigating the
role of SDH mutations in HPGL. Indeed the findings of these
prior reports indicate parallel mechanisms between succinate and
fumarate-induced pseudohypoxic drive as succinate may interfere
with HPH activity. As a by-product of HIF hydroxylation by HPH,
the cosubstrate 2-OG undergoes oxidative decarboxylation to
form succinate (Gottlieb and Tomlinson, 2005). Selak et al (2005)
demonstrated that inhibition of SDH with siRNA resulted in
elevated HIF levels owing to inhibition of HPH. Furthermore, these
investigators demonstrated that succinate is able to inhibit HPH
directly, most likely via product feedback inhibition (Selak et al,
2005). Pollard et al (2005b) demonstrated strong nuclear HIF-1a
expression in tumours (both paragangliomas and pheochromo-
cytomas) from HPGL patients. Paragangliomas from patients with
known germline SDHB mutations have been found to have
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multiple reports have reported enhanced expression of HIF-
regulated genes including VEGF in tumours with known SDH
mutations (Gimenez-Roqueplo et al, 2001; Pollard et al, 2005a).
Although these studies focus on the effects of an acute change in
SDH activity, paragangliomas from patients with germline SDHB
mutations have been shown to have chronically elevated levels of
succinate (Pollard et al, 2005b). In concordance with this finding is
a recent report indicating that SDHA mutant fibroblasts accumu-
late succinate and that succinate facilitates nuclear translocation of
HIF (Briere et al, 2005).
Taken together, these data provide compelling evidence for a
link between Kreb’s cycle dysfunction and oncogenesis. Despite
possibly sharing a similar mechanism for tumorigenesis, HLRCC
and HPGL represent two distinct syndromes with minimal overlap.
There are no reported cases of pheochromocytoma in patients with
known germline FH mutations. However, there is one report of
early onset RCC in three patients with germline SDHB mutations
(Vanharanta et al, 2004). Two of the three patients were from the
same family and all three RCCs were found to have lost the wild-
type SDHB allele. This small data set provides further evidence that
TCA cycle dysregulation plays an important role in RCC aetiology.
CONCLUSION
Hereditary leiomyomatosis and renal cell cancer is a hereditary
cancer syndrome predisposing individuals to the development of
aggressive kidney cancers. These individuals are known to harbour
a germline mutation of FH, which codes for the enzyme that
catalyses the conversion of fumarate to malate. Although multiple
mechanisms of tumorigenesis have been proposed, the preponder-
ance of data thus far supports a role for pseudohypoxic drive
involving fumarate-dependent HIF activation. The link between
FH inactivation and HIF appears to involve inhibition of HPH
activity (and thus pVHL recognition of HIF) via fumarate
accumulation. By a similar mechanism, elevated levels of succinate
may be responsible for pseudohypoxic drive in the context of
paragangliomas/pheochromocytomas in patients with germline
SDH mutations. These studies provide a unique molecular basis for
the Warburg effect. The Warburg effect refers to the preferential
derivation of energy by rapidly dividing cancer cells from glucose
metabolism via glycolysis rather than oxidative phosphorylation
despite adequate intracellular oxygen levels. We have shown that
experimental depletion of FH results in acute upregulation of
GLUT1 protein, glucose uptake, and lactate production in
normoxic cells (Isaacs et al, 2005). Succinate accumulation may
produce a similar phenotype (Selak et al, 2005). Lu et al (2005)
have proposed that various glucose metabolites promote HIF
stabilisation and reduced expression of TCA cycle enzymes, thus
constituting a feed-forward signalling mechanism favouring
continued dependence on glycolysis as an energy source. This
dependence is further driven by growth factors frequently
associated with oncogenesis (e.g., insulin, insulin-like growth
factor-1, epidermal growth factor, heregulin) that stimulate the
AKT–mTOR pathway and subsequently the rate of HIF translation
(Majumder et al, 2004). Thus, although the molecular mechanisms
responsible for this metabolic switch are complex and likely
multifactorial, the ultimate upregulation of HIF may provide a
cellular milieu supportive of continuously elevated glycolysis and
suppressed oxidative phosphorylation. Continued investigation of
the molecular mechanisms underlying pseudohypoxia will there-
fore elucidate new targets for molecular therapeutics that are
applicable to both inherited and sporadic kidney cancers.
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